China National Accord Medicines Corp Ltd

The company maintains a debt-to-equity ratio of 0.24, indicating a conservative capital structure with limited leverage. Free cash flow of 1.78 billion CNY supports liquidity, though net cash is negative after subtracting total debt. Return on equity of 6.1% and return on assets of 2.31% suggest modest profitability relative to asset base and equity. Operating income of 1.51 billion CNY and net income of 1.14 billion CNY reflect a gross margin of 10.67% (7.83 billion CNY gross profit on 73.42 billion CNY revenue). These metrics fall below the median for the Pharmaceuticals industry, which typically exhibits higher gross margins due to R&D intensity and pricing power. Revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond China. This creates exposure to domestic regulatory shifts and healthcare policy changes. Outlook data is not available for the current or next fiscal year, but historical revenue growth cannot be determined from the provided data. Analysts assign a mean price target of 26.86 CNY, with a median of 26.07 CNY and a high of 36.33 CNY. Liquidity risk is rated as medium due to negative net cash after debt, while dilution risk is low. No recent events or filings are disclosed in the provided data.